Exact Sciences
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
The firm is engaging with regulators about its recently validated Ataraxis Breast test, which it hopes to make available for clinical use next year.
In an indirect comparison study by researchers in Germany, a fecal immunochemical test showed similar sensitivity and specificity as Exact Sciences' Cologuard Plus test.
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
Exact Sciences Nabs FDA Approval for Cologuard Plus Assay
The stool-based test is the next-generation version of Exact's existing Cologuard test for colorectal cancer screening.